Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Novel Therapies for Hemophilia: What Does the Evidence Show?

Premiere Date: Monday, December 23, 2019

This activity offers CE credit for:

1. Physicians (CME)
2. Pharmacists (ACPE)
3. ABIM (MOC)
4. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Thursday, December 31, 2020
Note: Credit Is No Longer Available

Faculty

Guy A. Young, MD  Director, Hemostasis and Thrombosis Center Director, Clinical Coagulation Laboratory Children's Hospital Los Angeles Professor of Pediatrics University of Southern California Keck School of Medicine Los Angeles, CA

Maya Bloomberg, MSN, APRN, FNP-BC  University of Miami Miller School of Medicine Hemophilia Treatment Center Miami, FL

James T. Kenney, RPh, MBA  President, JTKENNEY, LLC President, Academy of Managed Care Pharmacy (AMCP) Alexandra, VA

Statement of Need

The expanding number of hemophilia therapies has led to a complicated treatment decision-making process. There are many barriers to implementation of these newer therapies, including gaps in clinicians' knowledge regarding the latest data on the safety and efficacy of these therapies.

In the first module of this CME Outfitters 3-part snack series on prior authorization for hemophilia, expert faculty discuss new and emerging therapies for hemophilia and the evidence for use in patients with hemophilia.

We encourage learners to complete all 3 CME Snacks in this series to receive a Certificate of Excellence in Prior Authorization.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Apply the latest clinical evidence on the efficacy and safety of new and emerging therapies to treatment decisions for individuals with hemophilia.

The following learning objectives pertain only to those requesting CNE or CPE credit:

• Identify the latest clinical evidence on the efficacy and safety of new and emerging therapies for treatment decisions for individuals with hemophilia.

Financial Support

Supported by educational grants from CSL Behring LLC and Genentech.

Target Audience

Hematologists, physician assistants, nurse practitioners, nurses, pharmacists, medical assistants, and patients.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs) Universal Activity Number:
Enduring: 0376-0000-19-047-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Learning Format:
Enduring Material

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit^TM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy/.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Young reports that he receives grants from Genentech, Inc. He is a consultant for Bayer Corporation; CSL Behring; Freeline; Genentech, Inc.; Grifols; Novo Nordisk; Roche; Spark Therapeutics, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Unique Pharmaceuticals Ltd.

Maya Bloomberg, MSN, APRN, FNP-BC, reports that she is an advisory board participant for Bayer Corporation; Genentech, Inc.; Global Blood Therapeutics Inc.; Octapharma Plasma Inc.; and Takeda Pharmaceuticals U.S.A., Inc.. She is on the speakers bureau for Alexion Pharmaceuticals, Inc.; Bayer Corporation; and Genentech, Inc.

James T. Kenney, RPh, MBA, has no disclosures to report.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Kavitha Ramachandran, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).